Abstract:Yao-Kuang Wu, 1, 2 Wen-Lin Su, 1, 2 Mei-Chen Yang, 1, 2 Sin-Yi Chen, 1 Chih-Wei Wu, 1 Chou-Chin Lan 1, 2 1 Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; 2 School of Medicine, Tzu-Chi University, Hualien, Taiwan Correspondence: Chou-Chin Lan Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 289, Jianguo Road, Xindian District, New Taipei City, Taiwan Tel +886-2-66289779 ext 5709 Fax +886-2-66289009 Email Background: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease with exacerbations causing hospitalizations, morbidity, and mortality. COPD exacerbation causes a substantial health impact, and its subtypes might differ in prognosis and treatment response. Methods: This study evaluated the factors of COPD exacerbations and explored the probabilities of frequent severe COPD exacerbations. Categorical and continuous variables between groups were compared. The hazard ratio (HR) and the probability of no hospital readmission were also estimated. Results: A total of 617 COPD patients were enrolled and comprised the frequent exacerbator (N = 226) and the non-frequent exacerbator (N = 391) groups. The frequent exacerbator group significantly displayed a higher eosinophil count (EC; p=0.004), a higher percentage of the frequent severe acute exacerbation history before the index hospitalization (IH; p < 0.001), a lower FEV1 value (p=0.001), and a higher triple combination inhaler prior and following the IH (p < 0.001 and p=0.002) than the non-frequent exacerbator one. Increasing age (aOR of 1.02), higher EC (aOR of 1.09), and lower FEV1 value (aOR of 0.72) were significantly associated with an increased hospital readmission risk. The readmission rate and risk were higher in patients with a history of frequent severe acute exacerbation (aHR of 3.38) than those without severe acute exacerbation. Cases treated with the triple combination inhaler before the IH had a higher readmission rate and risk than non-users. Conclusion: Patients with EC ≥ 2%, FEV1 < 50%, or frequent severe acute exacerbation history before the IH have a higher risk of being diagnosed with a frequent exacerbator phenotype. Besides, higher age, triple combination inhaler before the IH, and smoking might be independently correlated with the frequent readmission risk within 1-year post-exacerbation. A better comprehension of the COPD exacerbation mechanism may further identify the best course of preventative strategy and lead to novel interventions. Keywords: chronic obstructive pulmonary disease, COPD, forced expiratory volume in one second, FEV1, forced vital capacity, FVC, index hospitalization, eosinophil count Chronic obstructive pulmonary disease (COPD) is a chronic inflammation disease of the airways characterized by an incompletely reversible airflow limitation. 1 The COPD disease progression is punctuated by periodic deterioration in respiratory symptoms called exacerbations that cause most hospitalizations followed by significant morbidity and mortality. 2 COPD exacerbations could lead to hospital admissions contributing to a significant clinical and economic load worldwide. 3 Exacerbations might get more frequent and more severe as COPD progresses, 4 and their recurrence is correlated with a lung function decline and health status of patients. 5 The hospitalization cost of severe COPD exacerbation can be 60 times more expensive than mild or moderate exacerbations managed by primary care services. 6 For patients surviving after a COPD exacerbation-related hospitalization, readmission is a significant problem. Identifying and reducing risk factors for frequent readmission is therefore essential. 7 The official American Thoracic Society workshop report on reducing COPD readmission emphasized the requirement to identify risk factors for COPD readmissions. 8 Acute exacerbations are an essential feature in COPD's natural history, and identifying the frequent exacerbator phenotype may benefit from avoiding these complications. Furthermore, identifying COPD patients with risk factors associated with severe exacerbations may alert physicians, induce closer follow-up, and adopt preventive measures. Identification of biomarkers enables phenotype-driven approaches to manage and prevent exacerbations. COPD exacerbations are heterogeneous, and various phenotypes that differ in biological basis, prognosis, and response to therapy have been -Abstract Truncated-

Unravelling the "frequent exacerbator" phenotype in cystic fibrosis

Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis

Characterization Associated with the Frequent Severe Exacerbator Phenotype in COPD Patients

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

Outpatient management of pulmonary exacerbations in children with cystic fibrosis

Predictors of Exacerbation Frequency in Chronic Obstructive Pulmonary Disease

Association of T-cell receptor {beta} repertoire diversity and frequent exacerbation phenotype in COPD

Exome and Sputum Microbiota as Predictive Markers of Frequent Exacerbations in Chronic Obstructive Pulmonary Disease

Pulmonary exacerbations in early cystic fibrosis lung disease are marked by strong modulation of CD3 and PD-1 on luminal T cells

Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis

Clinical and transcriptomic features of persistent exacerbation‐prone severe asthma in U‐BIOPRED cohort

Predictive Value of Physiological Values and Symptom Scores for Exacerbations in Bronchiectasis and Chronic Obstructive Pulmonary Disease With Frequent Exacerbations: Longitudinal Observational Cohort Study

Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease

Exacerbation-like events in the 12 months prior to identification of chronic respiratory conditions in a primary care population

Inflammation in children with cystic fibrosis: contribution of bacterial production of long-chain fatty acids

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations

Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis

A Pulmonary Exacerbation Risk Score among Cystic Fibrosis Patients Not Receiving Recommended Care.

Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

The Non-Invasive Detection of Pulmonary Exacerbations in Disorders of Mucociliary Clearance with Breath Analysis: A Systematic Review